(ASX:BGT)

Investor Presentation

October 2018

The Global Problem of Pest Control

The Ag-Chem industry is seeking new & safer chemistry as global resistance continues to worsen

Pest Resistance

Pests are rapidly developing resistance to current insecticides

Environmental Impact

Public outrage at incumbent products' toxic impact on bees & other beneficial insects

Crop Losses

Insects destroy up to 26% of global crop production, reducing food availability, & increasing cost[1]

Grain Losses

Storage pests can cause 25% - 70% loss in stored grain[2]

Vector-borne Diseases

Cause 17% of global illness & disability eg Malaria, Dengue fever & Zika virus[3]

Consumer Products

Consumers are demanding natural insecticide products

[1]*The Journal of Agricultural Science, Cambridge 2006,* [2]*Australian Grain Industry & Millennium Development, 2007* [3]*World Health Organization, 2015*

In recent years the problem has worsened

Increasing number of resistant species



New insecticides are increasingly elusive



New compounds must demonstrate multiple qualities

Efficacy

Compound must be effective, either alone or in combination with incumbent insecticides, in controlling pests

Safe Chemistry

New '*soft chemistries*' *are* required, which don't adversely impact the environment or beneficial insects (e.g. bees)

Novel Mode of Action

Compounds must have a novel Mode of Action (MoA) to existing chemistries to be effective in controlling resistant pests

Scalability

Technology must be able to be produced at a commercial cost and volume

Bio-Gene's technology addresses these needs

Efficacy

Data shows Flavocide™ & Qcide™ are highly effective for controlling resistant pests across:

1) Crop Protection & Grain Storage
2) Public Health
3) Consumer Products

Safe Chemistry

Trials show relatively low toxicity to bees & other beneficial insects

Tox studies to date indicate no observable adverse effects to mammals

Novel Mode of Action

Bio-Gene's compounds operate via a novel Mode of Action, which addresses pest resistance

Scalability

CSIRO collaboration has refined production to be commercially viable

Bio-Gene has two unique compounds

Qcide™

Natural Compound

Extract of an Australian eucalypt: ‘Gypmie Messmate’

Qcide™ is well suited to applications in consumer products, along with public health & crop protection where a natural product is preferred

Flavocide™

Nature Identical Compound

A chemical process is used to produce a ‘synthetic copy’ of the compound that can be mass produced

Well suited for broad & larger verticals:

1) Crop Protection
2) Public Health

Well-defined pathway to commercialisation

Testing & Data Generation

Create suite of trial data & IP relating to efficacy, toxicity, mode of action and manufacturing

Introductory Commercial Discussions Globally

Present Bio-Gene to major Ag-Chem, Government Agencies, NGO's & Philanthropic Organisations

Evaluation Partnerships

Establish evaluation partnerships, to determine specific market applications

Commercial Deals

Progress evaluation partnerships to a commercial deal

Bio-Gene has delivered on multiple milestones in 2018

Significant Suite of Trial Data for Proof of Concept Efficacy Testing

Toxicology Studies to Support Registration

Multiple Partnership Discussions

Expanded Knowledge of Mode of Action

Strengthened Intellectual Property

Improved Manufacturing Capability

Appointed Expert Advisors

Trial Data for Proof of Concept Efficacy Testing

Objective
Demonstrate effectiveness against pests that are resistant to other classes of chemistry

Create suite of testing data across key verticals, to de-risk technology, & support discussions with major Ag-Chem businesses

Results achieved in 2018 to date
Overwhelmingly positive results across the key verticals

- Proof of control of resistant pests
- Control of pests resistant to major chemical groups
- Control of major global pest groups

Data shows low toxicity to bees & other beneficial insects

Next Steps
Enhance data set through evaluation partnerships for specific pest focussed testing programs

Toxicology Studies to Support Registration

Objective
Demonstrate the safety of the technology & fulfil registration requirements

Achieved in 2018
Continued formal toxicology & environmental safety studies with accredited third parties to perform necessary testing:

- 28-day Oral & Dermal Tox Studies completed for Flavocide™
- Tox-studies commencing for Qcide™

Next Steps
Design next level of tox studies to progress towards registration

Multiple Partnership Discussions

Objective
Identify appropriate partners for product evaluation & development

Achieved in 2018
Held multiple meetings in Australia, Europe, US & Asia, with Major Ag-Chem Producers, Government agencies & Not-for-Profit Organisations, covering all key verticals

Continued strong interest in our technology

Next Steps
Establish evaluation partnerships with strategic partners, optimising & testing **Qcide™** or **Flavocide™** in combination with existing products

Expanded Knowledge of Mode of Action

Objective
Clarify the specifics of the Mode of Action (“MoA”) to apply for a new class of chemistry via IRAC & support IP portfolio

Achieved in 2018
- MoA confirmed via electrophysiological testing by world-class group
- Supported by multiple efficacy test data against different resistant pests

Next Steps
Additional testing underway to elucidate specific sites of activity within the MoA
From these results, develop a peer-review paper for submission to the Insect Resistance Action Committee for new class of chemistry

Strengthened Intellectual Property

Objective
Generate data to support current & future patent filings & Intellectual Property

Achieved in 2018
Two additional patent applications lodged
Significant manufacturing Intellectual Property

Next Steps
Continue to identify opportunities to develop Intellectual Property, & implement appropriate data generating studies

Improved Manufacturing Capability

Objective
Improve cost & yield of current manufacturing processes for Qcide™ & Flavocide™

Achieved in 2018
- Partnership with CSIRO has delivered substantial improvement in the cost of production of Flavocide™ with improved purity and yield
- Partnership with James Cook University underway to improve tree oil production & extraction of Qcide™ from production trees

Next Steps
- Pilot plant trials to scale up production of Flavocide™
- Implement development plans for tree cloning & oil extraction

Appointed Expert Advisors

Objective
Engage specialists in related fields to assess data & assist with next stage testing

DOUG RATHBONE

Advisor to the BGT Board

- >40 years experience in agriculture.
- MD of Nufarm for >15 years during which Nufarm became one of Australia's most successful agricultural firms with global sales >$2.5B

PROF. CATHERINE HILL

Purdue University

BGT Scientific Advisory Board Member

- Purdue University, Dept. of Entomology
- Showalter Faculty Scholar
- President's Fellow for the Life Sciences
- Authority in new insecticide development & novel chemistry

NEIL ANDERSON

Chemistry & Manufacturing Consultant

- Industrial Chemist, employed by Monsanto 40 years
- Specialist in formulation development, production, & process management
- Qualified for manufacturing plant audits, quality & environmental management

Next Steps

- Continue to leverage knowledge of advisory Board
- Identify & appoint further experts whose knowledge aligns with commercialisation plans

Q&A

*Click links to launch Articles

Financial Overview

Strong Cash Position

BGT has a well funded balance sheet with ~$6.7m in cash (as at end FY18), providing a ~2 year runway

Capital Structure & Financials	
Shares on Issue	128m
Share Price (Oct-18)	$0.13
12-month Range	$0.10 – $0.28
Market Cap	$16.6m
Cash Balance (Jun-18)	$6.7m



	Options Issued	Exercise Price	Expiry
Broker Options	2,000,000	20c	24/11/2020
Options*	25,056,730	20c	4/12/2018

** Options were issued to all shareholders on a 1:5 basis pursuant to Prospectus dated 1/03/2018*

Board & Management

DON BRUMLEY

Non-Executive Chairman

- 25+ years as a senior partner & leader of Ernst & Young – Oceania
- Significant experience across IPOs, transactions, audit & advising growing entrepreneurial companies

RICHARD JAGGER

CEO & Managing Director

- 20+ years working in agriculture globally
- Most recently employed as Managing Director of Sinochem Australia
- Previously spent 15+ years at Monsanto in various management roles



PETER MAY

Executive Director, R & D

- 20+ years experience in crop protection market with companies Orica & Crop Care Australasia (now Nufarm)
- Founded Xavca, consulted to companies such as Syngenta & Sorex (BASF)
- Former CEO & Chairman of BioProspect (now Medibio, ASX:MEB)

ROBERT KLUPACS

Non-Executive Director

- 30+ years corporate experience in international tech development
- Previously MD & CEO of ASX-listed Circadian Technologies Ltd
- Previously MD & CEO of ES Cell International Pte Ltd
- Registered Australian patent attorney

KEVIN RUMBLE

Non-Executive Director

- Founding Director of Bio-Gene
- 20+ years experience in new plant propagation, farming & live plant transport techniques
- Involved in the development of Qcide™ & development of Flavesone as a first step in the commercialisation of Flavocide™



ROGER MCPHERSON

Chief Financial Officer & Company Secretary

- 15+ years experience as CFO & Company Secretary across both listed & unlisted companies
- Experience in the pharma manufacturing, biotech & biopharma industries
- Previously CFO & Co-Sec of TPI Enterprises (ASX:TPE)

BIO-GENE
TECHNOLOGY
LTD

Richard Jagger
CEO
+61 3 9628 4178
richardj@bio-gene.com.au

Roger McPherson
CFO, Co. Sec.
+61 3 9628 4178
rogerm@bio-gene.com.au